New shot aims to stop bleeding in rare blood disorder
NCT ID NCT07115004
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 study tests a drug called VGA039, given as a shot under the skin, to prevent bleeding in people with Von Willebrand disease. The trial will include 60 patients aged 12 to 75 who have frequent bleeding episodes. Researchers will track how well the drug reduces bleeds and check for side effects over about a year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VGA039 (a drug given as a shot under the skin)
What this could lead to
If it works, this could offer a new preventive treatment to reduce bleeding episodes in people with Von Willebrand disease.
What could go wrong
This is still a phase 3 trial with only 60 participants, so results may not apply to everyone. There are risks like allergic reactions or side effects from the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VON WILLEBRAND DISEASE (VWD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arkansas Children's Hospital
RECRUITINGLittle Rock, Arkansas, 72202, United States
-
Charlotte Maxeke Johannesburg Academic Hospital School of Pathology Clinical Haematologist
RECRUITINGJohannesburg, 2194, South Africa
-
Children's Healthcare of Atlanta
RECRUITINGAtlanta, Georgia, 30329, United States
-
Emory University Hospital
RECRUITINGAtlanta, Georgia, 30308, United States
Contact Phone: •••-•••-••••
-
Frankfurt University Hospital (Universitätsmedizin Frankfurt)
RECRUITINGFrankfurt, 60596, Germany
-
Hemophilia Center of Western PA
RECRUITINGPittsburgh, Pennsylvania, 15213, United States
-
K Eristavi National Center of Experimental and Clinical Surgery (ქირურგიის ეროვნული ცენტრი)
RECRUITINGTbilisi, 0159, Georgia
-
Luskin Orthopaedic Institute For Children
RECRUITINGLos Angeles, California, 90007, United States
-
Science 37, Inc. (Virtual Clinical MetaSite)
RECRUITINGMorrisville, North Carolina, 27560, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UC Davis Medical Center
RECRUITINGSacramento, California, 95817, United States
-
UT Southwestern Children's Hospital
RECRUITINGDallas, Texas, 75235, United States
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
-
University of Minnesota
RECRUITINGMinneapolis, Minnesota, 55455, United States
-
Washington Center for Bleeding Disorders
RECRUITINGSeattle, Washington, 98101, United States
Contact Email: •••••@•••••